Proactiveinvestors USA & Canada AIM ImmunoTech Inc. https://ca.proactiveinvestors.com Proactiveinvestors USA & Canada AIM ImmunoTech Inc. RSS feed en Fri, 14 Aug 2020 09:34:37 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) AIM Immunotech forms Phase 1/2a clinical trial agreement to fight the coronavirus https://ca.proactiveinvestors.com/companies/news/924632/aim-immunotech-forms-phase-12a-clinical-trial-agreement-to-fight-the-coronavirus-924632.html Mon, 20 Jul 2020 15:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/924632/aim-immunotech-forms-phase-12a-clinical-trial-agreement-to-fight-the-coronavirus-924632.html AIM ImmunoTech inks pact with Roswell Park to test Ampligen as part of an antiviral treatment combo for COVID-19 among cancer patients https://ca.proactiveinvestors.com/companies/news/923821/aim-immunotech-inks-pact-with-roswell-park-to-test-ampligen-as-part-of-an-antiviral-treatment-combo-for-covid-19-among-cancer-patients-923821.html Thu, 09 Jul 2020 11:55:00 -0400 https://ca.proactiveinvestors.com/companies/news/923821/aim-immunotech-inks-pact-with-roswell-park-to-test-ampligen-as-part-of-an-antiviral-treatment-combo-for-covid-19-among-cancer-patients-923821.html AIM ImmunoTech to provide its drug Ampligen to Japanese government agency and a global pharma company for coronavirus vaccine tests https://ca.proactiveinvestors.com/companies/news/923523/aim-immunotech-to-provide-its-drug-ampligen-to-japanese-government-agency-and-a-global-pharma-company-for-coronavirus-vaccine-tests-923523.html Mon, 06 Jul 2020 15:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/923523/aim-immunotech-to-provide-its-drug-ampligen-to-japanese-government-agency-and-a-global-pharma-company-for-coronavirus-vaccine-tests-923523.html AIM ImmunoTech green-lit to import chronic fatigue syndrome drug into Argentina https://ca.proactiveinvestors.com/companies/news/922460/aim-immunotech-green-lit-to-import-chronic-fatigue-syndrome-drug-into-argentina-922460.html Mon, 22 Jun 2020 14:12:00 -0400 https://ca.proactiveinvestors.com/companies/news/922460/aim-immunotech-green-lit-to-import-chronic-fatigue-syndrome-drug-into-argentina-922460.html AIM ImmunoTech wins approval to import chronic fatigue syndrome drug Ampligen to Argentina https://ca.proactiveinvestors.com/companies/news/921928/aim-immunotech-wins-approval-to-import-chronic-fatigue-syndrome-drug-ampligen-to-argentina-921928.html Mon, 15 Jun 2020 14:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/921928/aim-immunotech-wins-approval-to-import-chronic-fatigue-syndrome-drug-ampligen-to-argentina-921928.html AIM ImmunoTech files provisional patent application for Ampligen as treatment for COVID-19 induced fatigue https://ca.proactiveinvestors.com/companies/news/921729/aim-immunotech-files-provisional-patent-application-for-ampligen-as-treatment-for-covid-19-induced-fatigue-921729.html Thu, 11 Jun 2020 12:18:00 -0400 https://ca.proactiveinvestors.com/companies/news/921729/aim-immunotech-files-provisional-patent-application-for-ampligen-as-treatment-for-covid-19-induced-fatigue-921729.html AIM ImmunoTech green-lit by the FDA for its trial to treat coronavirus patients with cancer https://ca.proactiveinvestors.com/companies/news/920194/aim-immunotech-green-lit-by-the-fda-for-its-trial-to-treat-coronavirus-patients-with-cancer-920194.html Thu, 21 May 2020 17:46:00 -0400 https://ca.proactiveinvestors.com/companies/news/920194/aim-immunotech-green-lit-by-the-fda-for-its-trial-to-treat-coronavirus-patients-with-cancer-920194.html AIM ImmunoTech gets nod from FDA for Ampligen combo drug trial in coronavirus patients with cancer https://ca.proactiveinvestors.com/companies/news/920093/aim-immunotech-gets-nod-from-fda-for-ampligen-combo-drug-trial-in-coronavirus-patients-with-cancer-920093.html Thu, 14 May 2020 19:53:00 -0400 https://ca.proactiveinvestors.com/companies/news/920093/aim-immunotech-gets-nod-from-fda-for-ampligen-combo-drug-trial-in-coronavirus-patients-with-cancer-920093.html AIM ImmunoTech reveals most recent advancements with its potential coronavirus treatment https://ca.proactiveinvestors.com/companies/news/917100/aim-immunotech-reveals-most-recent-advancements-with-its-potential-coronavirus-treatment-917100.html Mon, 13 Apr 2020 14:32:00 -0400 https://ca.proactiveinvestors.com/companies/news/917100/aim-immunotech-reveals-most-recent-advancements-with-its-potential-coronavirus-treatment-917100.html AIM ImmunoTech inks deal to research vaping device as a vehicle for Ampligen to treat coronavirus https://ca.proactiveinvestors.com/companies/news/916966/aim-immunotech-inks-deal-to-research-vaping-device-as-a-vehicle-for-ampligen-to-treat-coronavirus-916966.html Mon, 06 Apr 2020 19:28:00 -0400 https://ca.proactiveinvestors.com/companies/news/916966/aim-immunotech-inks-deal-to-research-vaping-device-as-a-vehicle-for-ampligen-to-treat-coronavirus-916966.html AIM ImmunoTech seeking clinical trials to assess Ampligen as a potential protective and early-onset treatment for coronavirus https://ca.proactiveinvestors.com/companies/news/916964/aim-immunotech-seeking-clinical-trials-to-assess-ampligen-as-a-potential-protective-and-early-onset-treatment-for-coronavirus-916964.html Thu, 26 Mar 2020 20:46:00 -0400 https://ca.proactiveinvestors.com/companies/news/916964/aim-immunotech-seeking-clinical-trials-to-assess-ampligen-as-a-potential-protective-and-early-onset-treatment-for-coronavirus-916964.html AIM ImmunoTech reaches deal with Japan to test Ampligen as coronavirus treatment https://ca.proactiveinvestors.com/companies/news/914673/aim-immunotech-reaches-deal-with-japan-to-test-ampligen-as-coronavirus-treatment-914673.html Tue, 10 Mar 2020 15:06:00 -0400 https://ca.proactiveinvestors.com/companies/news/914673/aim-immunotech-reaches-deal-with-japan-to-test-ampligen-as-coronavirus-treatment-914673.html AIM ImmunoTech hopes to take the battle against COVID-19 to the front lines of China https://ca.proactiveinvestors.com/companies/news/914213/aim-immunotech-hopes-to-take-the-battle-against-covid-19-to-the-front-lines-of-china-914213.html Tue, 03 Mar 2020 15:07:00 -0500 https://ca.proactiveinvestors.com/companies/news/914213/aim-immunotech-hopes-to-take-the-battle-against-covid-19-to-the-front-lines-of-china-914213.html AIM ImmunoTech files patent applications to market Ampligen as coronavirus treatment https://ca.proactiveinvestors.com/companies/news/912708/aim-immunotech-files-patent-applications-to-market-ampligen-as-coronavirus-treatment-912708.html Tue, 11 Feb 2020 21:26:00 -0500 https://ca.proactiveinvestors.com/companies/news/912708/aim-immunotech-files-patent-applications-to-market-ampligen-as-coronavirus-treatment-912708.html AIM ImmunoTech CEO offers corporate update on lead drug, fundraising efforts https://ca.proactiveinvestors.com/companies/news/908870/aim-immunotech-ceo-offers-corporate-update-on-lead-drug-fundraising-efforts-908870.html Tue, 10 Dec 2019 16:02:00 -0500 https://ca.proactiveinvestors.com/companies/news/908870/aim-immunotech-ceo-offers-corporate-update-on-lead-drug-fundraising-efforts-908870.html AIM ImmunoTech says raised around $10M from public markets over past few months to support lead drug cancer candidate https://ca.proactiveinvestors.com/companies/news/904407/aim-immunotech-says-raised-around-10m-from-public-markets-over-past-few-months-to-support-lead-drug-cancer-candidate-904407.html Tue, 08 Oct 2019 15:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/904407/aim-immunotech-says-raised-around-10m-from-public-markets-over-past-few-months-to-support-lead-drug-cancer-candidate-904407.html AIM ImmunoTech’s Ampligen study on brain-metastatic breast cancer funded by DoD’s $6.42M award to Roswell Park https://ca.proactiveinvestors.com/companies/news/903066/aim-immunotechs-ampligen-study-on-brain-metastatic-breast-cancer-funded-by-dods-642m-award-to-roswell-park-903066.html Thu, 19 Sep 2019 13:20:00 -0400 https://ca.proactiveinvestors.com/companies/news/903066/aim-immunotechs-ampligen-study-on-brain-metastatic-breast-cancer-funded-by-dods-642m-award-to-roswell-park-903066.html Hemispherx Biopharma changes name to AIM ImmunoTech Inc to reflect flagship drug Ampligen https://ca.proactiveinvestors.com/companies/news/901424/hemispherx-biopharma-changes-name-to-aim-immunotech-inc-to-reflect-flagship-drug-ampligen-901424.html Fri, 23 Aug 2019 15:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/901424/hemispherx-biopharma-changes-name-to-aim-immunotech-inc-to-reflect-flagship-drug-ampligen-901424.html Hemispherx Biopharma releases 'well tolerated' data for Ampligen ovarian cancer treatment https://ca.proactiveinvestors.com/companies/news/901049/hemispherx-biopharma-releases--well-tolerated--data-for-ampligen-ovarian-cancer-treatment-901049.html Mon, 19 Aug 2019 13:19:00 -0400 https://ca.proactiveinvestors.com/companies/news/901049/hemispherx-biopharma-releases--well-tolerated--data-for-ampligen-ovarian-cancer-treatment-901049.html Hemispherx Biopharma makes steady progress in cancer clinical trials https://ca.proactiveinvestors.com/companies/news/900890/hemispherx-biopharma-makes-steady-progress-in-cancer-clinical-trials-900890.html Thu, 15 Aug 2019 18:19:00 -0400 https://ca.proactiveinvestors.com/companies/news/900890/hemispherx-biopharma-makes-steady-progress-in-cancer-clinical-trials-900890.html NA Proactive news snapshot: Marrone Bio Innovations, ElectraMeccanica Vehicles, Silvercorp Metals, Universal mCloud UPDATE … https://ca.proactiveinvestors.com/companies/news/900388/na-proactive-news-snapshot-marrone-bio-innovations-electrameccanica-vehicles-silvercorp-metals-universal-mcloud-update---900388.html Thu, 08 Aug 2019 22:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/900388/na-proactive-news-snapshot-marrone-bio-innovations-electrameccanica-vehicles-silvercorp-metals-universal-mcloud-update---900388.html Hemispherx reports positive survival data linked to stage 4 ovarian cancer using Ampligen as a combination therapy https://ca.proactiveinvestors.com/companies/news/900376/hemispherx-reports-positive-survival-data-linked-to-stage-4-ovarian-cancer-using-ampligen-as-a-combination-therapy-900376.html Thu, 08 Aug 2019 12:05:00 -0400 https://ca.proactiveinvestors.com/companies/news/900376/hemispherx-reports-positive-survival-data-linked-to-stage-4-ovarian-cancer-using-ampligen-as-a-combination-therapy-900376.html Hemispherx Biopharma corrects reports that mistakenly inflated the value of its private placement https://ca.proactiveinvestors.com/companies/news/224926/hemispherx-biopharma-corrects-reports-that-mistakenly-inflated-the-value-of-its-private-placement-224926.html Fri, 02 Aug 2019 13:35:00 -0400 https://ca.proactiveinvestors.com/companies/news/224926/hemispherx-biopharma-corrects-reports-that-mistakenly-inflated-the-value-of-its-private-placement-224926.html Hemispherx Biopharma’s Ampligen treatment aims to disrupt the cancer market https://ca.proactiveinvestors.com/companies/news/223448/hemispherx-biopharmas-ampligen-treatment-aims-to-disrupt-the-cancer-market-223448.html Fri, 05 Jul 2019 16:36:00 -0400 https://ca.proactiveinvestors.com/companies/news/223448/hemispherx-biopharmas-ampligen-treatment-aims-to-disrupt-the-cancer-market-223448.html Hemispherx Biopharma CFO Adam Pascale to retire https://ca.proactiveinvestors.com/companies/news/223051/hemispherx-biopharma-cfo-adam-pascale-to-retire-223051.html Fri, 28 Jun 2019 11:25:00 -0400 https://ca.proactiveinvestors.com/companies/news/223051/hemispherx-biopharma-cfo-adam-pascale-to-retire-223051.html Hemispherx Biopharma makes progress with Phase 2 clinical trial to treat ovarian cancer https://ca.proactiveinvestors.com/companies/news/313819/hemispherx-biopharma-makes-progress-with-phase-2-clinical-trial-to-treat-ovarian-cancer-13819.html Thu, 20 Jun 2019 14:32:00 -0400 https://ca.proactiveinvestors.com/companies/news/313819/hemispherx-biopharma-makes-progress-with-phase-2-clinical-trial-to-treat-ovarian-cancer-13819.html Hemispherx Biopharma issues updates for ongoing immunotherapy trials of its drug Ampligen https://ca.proactiveinvestors.com/companies/news/222245/hemispherx-biopharma-issues-updates-for-ongoing-immunotherapy-trials-of-its-drug-ampligen-222245.html Mon, 17 Jun 2019 13:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/222245/hemispherx-biopharma-issues-updates-for-ongoing-immunotherapy-trials-of-its-drug-ampligen-222245.html Hemispherx Biopharma initiated with a Buy rating and $8 price target at Maxim https://ca.proactiveinvestors.com/companies/news/222173/hemispherx-biopharma-initiated-with-a-buy-rating-and-8-price-target-at-maxim-222173.html Fri, 14 Jun 2019 16:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/222173/hemispherx-biopharma-initiated-with-a-buy-rating-and-8-price-target-at-maxim-222173.html Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials https://ca.proactiveinvestors.com/companies/news/222000/hemispherx-treats-first-patient-with-cancer-drug-ampligen-in-phase-2-clinical-trials-222000.html Wed, 12 Jun 2019 20:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/222000/hemispherx-treats-first-patient-with-cancer-drug-ampligen-in-phase-2-clinical-trials-222000.html Hemispherx Biopharma shares soar as reverse split takes effect https://ca.proactiveinvestors.com/companies/news/221911/hemispherx-biopharma-shares-soar-as-reverse-split-takes-effect-221911.html Tue, 11 Jun 2019 17:10:00 -0400 https://ca.proactiveinvestors.com/companies/news/221911/hemispherx-biopharma-shares-soar-as-reverse-split-takes-effect-221911.html Hemispherx Biopharma board approves 1-for-44 reverse stock split https://ca.proactiveinvestors.com/companies/news/221323/hemispherx-biopharma-board-approves-1-for-44-reverse-stock-split-221323.html Fri, 31 May 2019 16:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/221323/hemispherx-biopharma-board-approves-1-for-44-reverse-stock-split-221323.html Hemispherx Biopharma’s well-funded to take promising cancer drug Ampligen through clinical trials https://ca.proactiveinvestors.com/companies/news/220438/hemispherx-biopharmas-well-funded-to-take-promising-cancer-drug-ampligen-through-clinical-trials-220438.html Thu, 16 May 2019 13:58:00 -0400 https://ca.proactiveinvestors.com/companies/news/220438/hemispherx-biopharmas-well-funded-to-take-promising-cancer-drug-ampligen-through-clinical-trials-220438.html Hemispherx Biopharma says FDA authorizes study using aspirin and flagship drug ampligen to treat prostate cancer https://ca.proactiveinvestors.com/companies/news/220151/hemispherx-biopharma-says-fda-authorizes-study-using-aspirin-and-flagship-drug-ampligen-to-treat-prostate-cancer-220151.html Mon, 13 May 2019 14:04:00 -0400 https://ca.proactiveinvestors.com/companies/news/220151/hemispherx-biopharma-says-fda-authorizes-study-using-aspirin-and-flagship-drug-ampligen-to-treat-prostate-cancer-220151.html Hemispherx sees potential commercialization of flagship drug ampligen for Chronic Fatigue Syndrome https://ca.proactiveinvestors.com/companies/news/219723/hemispherx-sees-potential-commercialization-of-flagship-drug-ampligen-for-chronic-fatigue-syndrome-219723.html Mon, 06 May 2019 16:20:00 -0400 https://ca.proactiveinvestors.com/companies/news/219723/hemispherx-sees-potential-commercialization-of-flagship-drug-ampligen-for-chronic-fatigue-syndrome-219723.html Hemispherx BioPharma reports positive results on ovarian cancer treatment https://ca.proactiveinvestors.com/companies/news/313171/hemispherx-biopharma-reports-positive-results-on-ovarian-cancer-treatment-13171.html Wed, 01 May 2019 12:40:00 -0400 https://ca.proactiveinvestors.com/companies/news/313171/hemispherx-biopharma-reports-positive-results-on-ovarian-cancer-treatment-13171.html Hemispherx Biopharma's stock soars on 'significant progress' in ovarian cancer study of Ampligen https://ca.proactiveinvestors.com/companies/news/219389/hemispherx-biopharma-s-stock-soars-on--significant-progress--in-ovarian-cancer-study-of-ampligen-219389.html Tue, 30 Apr 2019 14:49:00 -0400 https://ca.proactiveinvestors.com/companies/news/219389/hemispherx-biopharma-s-stock-soars-on--significant-progress--in-ovarian-cancer-study-of-ampligen-219389.html Hemispherx Biopharma appoints Ellen Lintal as chief accountant https://ca.proactiveinvestors.com/companies/news/313093/hemispherx-biopharma-appoints-ellen-lintal-as-chief-accountant-13093.html Wed, 24 Apr 2019 16:12:00 -0400 https://ca.proactiveinvestors.com/companies/news/313093/hemispherx-biopharma-appoints-ellen-lintal-as-chief-accountant-13093.html Hemispherx Biopharma promotes Ellen Lintal to chief accountant post https://ca.proactiveinvestors.com/companies/news/218893/hemispherx-biopharma-promotes-ellen-lintal-to-chief-accountant-post-218893.html Mon, 22 Apr 2019 12:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/218893/hemispherx-biopharma-promotes-ellen-lintal-to-chief-accountant-post-218893.html Hemispherx Biopharma doses first patient with Ampligen in Phase 1 advanced breast cancer study https://ca.proactiveinvestors.com/companies/news/312896/hemispherx-biopharma-doses-first-patient-with-ampligen-in-phase-1-advanced-breast-cancer-study-12896.html Fri, 05 Apr 2019 20:09:00 -0400 https://ca.proactiveinvestors.com/companies/news/312896/hemispherx-biopharma-doses-first-patient-with-ampligen-in-phase-1-advanced-breast-cancer-study-12896.html Hemispherx Biopharma kicks off Phase 1 trial to treat advanced breast cancer with key drug Ampligen https://ca.proactiveinvestors.com/companies/news/217775/hemispherx-biopharma-kicks-off-phase-1-trial-to-treat-advanced-breast-cancer-with-key-drug-ampligen-217775.html Tue, 02 Apr 2019 13:25:00 -0400 https://ca.proactiveinvestors.com/companies/news/217775/hemispherx-biopharma-kicks-off-phase-1-trial-to-treat-advanced-breast-cancer-with-key-drug-ampligen-217775.html Hemispherx Biopharma makes headway in advancing flagship cancer drug Ampligen in 2018 https://ca.proactiveinvestors.com/companies/news/217766/hemispherx-biopharma-makes-headway-in-advancing-flagship-cancer-drug-ampligen-in-2018-217766.html Tue, 02 Apr 2019 07:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/217766/hemispherx-biopharma-makes-headway-in-advancing-flagship-cancer-drug-ampligen-in-2018-217766.html Hemispherx Biopharma updates on current trials, gears up to begin 5 more https://ca.proactiveinvestors.com/companies/news/312623/hemispherx-biopharma-updates-on-current-trials-gears-up-to-begin-5-more-12623.html Fri, 15 Mar 2019 14:21:00 -0400 https://ca.proactiveinvestors.com/companies/news/312623/hemispherx-biopharma-updates-on-current-trials-gears-up-to-begin-5-more-12623.html Hemispherx rises as five trials for cancer drug Ampligen kick off this year https://ca.proactiveinvestors.com/companies/news/216405/hemispherx-rises-as-five-trials-for-cancer-drug-ampligen-kick-off-this-year-216405.html Wed, 13 Mar 2019 15:13:00 -0400 https://ca.proactiveinvestors.com/companies/news/216405/hemispherx-rises-as-five-trials-for-cancer-drug-ampligen-kick-off-this-year-216405.html Hemispherx Biopharma takes cancer war to new stage with drug Ampligen https://ca.proactiveinvestors.com/companies/news/216124/hemispherx-biopharma-takes-cancer-war-to-new-stage-with-drug-ampligen-216124.html Fri, 08 Mar 2019 08:00:00 -0500 https://ca.proactiveinvestors.com/companies/news/216124/hemispherx-biopharma-takes-cancer-war-to-new-stage-with-drug-ampligen-216124.html Hemispherx Biopharma expects gross proceeds of $5.3M from rights offering https://ca.proactiveinvestors.com/companies/news/215929/hemispherx-biopharma-expects-gross-proceeds-of-53m-from-rights-offering-215929.html Wed, 06 Mar 2019 14:33:00 -0500 https://ca.proactiveinvestors.com/companies/news/215929/hemispherx-biopharma-expects-gross-proceeds-of-53m-from-rights-offering-215929.html Hemispherx Biopharma gets green light from Dutch health regulators to extend access program for Ampligen to pancreatic cancer patients https://ca.proactiveinvestors.com/companies/news/215555/hemispherx-biopharma-gets-green-light-from-dutch-health-regulators-to-extend-access-program-for-ampligen-to-pancreatic-cancer-patients-215555.html Thu, 28 Feb 2019 17:45:00 -0500 https://ca.proactiveinvestors.com/companies/news/215555/hemispherx-biopharma-gets-green-light-from-dutch-health-regulators-to-extend-access-program-for-ampligen-to-pancreatic-cancer-patients-215555.html Hemispherx Biopharma extends $8M rights offering to March 5 https://ca.proactiveinvestors.com/companies/news/215543/hemispherx-biopharma-extends-8m-rights-offering-to-march-5-215543.html Thu, 28 Feb 2019 14:50:00 -0500 https://ca.proactiveinvestors.com/companies/news/215543/hemispherx-biopharma-extends-8m-rights-offering-to-march-5-215543.html Hemispherx Biopharma updates terms of $8 million rights offering, says senior management is participating https://ca.proactiveinvestors.com/companies/news/215432/hemispherx-biopharma-updates-terms-of-8-million-rights-offering-says-senior-management-is-participating-215432.html Wed, 27 Feb 2019 14:57:00 -0500 https://ca.proactiveinvestors.com/companies/news/215432/hemispherx-biopharma-updates-terms-of-8-million-rights-offering-says-senior-management-is-participating-215432.html Hemispherx Biopharma posts reminder of deadline for $8M rights issue https://ca.proactiveinvestors.com/companies/news/214489/hemispherx-biopharma-posts-reminder-of-deadline-for-8m-rights-issue-214489.html Tue, 12 Feb 2019 20:00:00 -0500 https://ca.proactiveinvestors.com/companies/news/214489/hemispherx-biopharma-posts-reminder-of-deadline-for-8m-rights-issue-214489.html Hemispherx announces start of Merck-supported ovarian cancer clinical drug trial https://ca.proactiveinvestors.com/companies/news/214370/hemispherx-announces-start-of-merck-supported-ovarian-cancer-clinical-drug-trial-214370.html Mon, 11 Feb 2019 14:47:00 -0500 https://ca.proactiveinvestors.com/companies/news/214370/hemispherx-announces-start-of-merck-supported-ovarian-cancer-clinical-drug-trial-214370.html Hemispherx Biopharma launches $8M rights issue to fund cancer drug trials https://ca.proactiveinvestors.com/companies/news/214188/hemispherx-biopharma-launches-8m-rights-issue-to-fund-cancer-drug-trials-214188.html Thu, 07 Feb 2019 13:22:00 -0500 https://ca.proactiveinvestors.com/companies/news/214188/hemispherx-biopharma-launches-8m-rights-issue-to-fund-cancer-drug-trials-214188.html Hemispherx Biopharma to begin two clinical trials at two major US cancer centers https://ca.proactiveinvestors.com/companies/news/311808/hemispherx-biopharma-to-begin-two-clinical-trials-at-two-major-us-cancer-centers-11808.html Fri, 11 Jan 2019 16:54:00 -0500 https://ca.proactiveinvestors.com/companies/news/311808/hemispherx-biopharma-to-begin-two-clinical-trials-at-two-major-us-cancer-centers-11808.html Hemispherx Biopharma's cancer drug Ampligen to be used in new oncology study https://ca.proactiveinvestors.com/companies/news/212180/hemispherx-biopharma-s-cancer-drug-ampligen-to-be-used-in-new-oncology-study-212180.html Tue, 08 Jan 2019 14:50:00 -0500 https://ca.proactiveinvestors.com/companies/news/212180/hemispherx-biopharma-s-cancer-drug-ampligen-to-be-used-in-new-oncology-study-212180.html Hemispherx Biopharma advances expanded access program for its therapy Ampligen https://ca.proactiveinvestors.com/companies/news/311707/hemispherx-biopharma-advances-expanded-access-program-for-its-therapy-ampligen-11707.html Fri, 04 Jan 2019 18:21:00 -0500 https://ca.proactiveinvestors.com/companies/news/311707/hemispherx-biopharma-advances-expanded-access-program-for-its-therapy-ampligen-11707.html Biotech companies dominate at Dawson James Securities Small Cap Growth Conference https://ca.proactiveinvestors.com/companies/news/208357/biotech-companies-dominate-at-dawson-james-securities-small-cap-growth-conference-208357.html Thu, 01 Nov 2018 20:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/208357/biotech-companies-dominate-at-dawson-james-securities-small-cap-growth-conference-208357.html Hemispherx Biopharma started with a Buy rating at Ascendiant Capital Markets https://ca.proactiveinvestors.com/companies/news/208270/hemispherx-biopharma-started-with-a-buy-rating-at-ascendiant-capital-markets-208270.html Wed, 31 Oct 2018 20:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/208270/hemispherx-biopharma-started-with-a-buy-rating-at-ascendiant-capital-markets-208270.html Hemispherx Biopharma to meet with FDA regarding Ampligen decision https://ca.proactiveinvestors.com/companies/news/93726/hemispherx-biopharma-to-meet-with-fda-regarding-ampligen-decision-41796.html Tue, 19 Mar 2013 19:57:00 -0400 https://ca.proactiveinvestors.com/companies/news/93726/hemispherx-biopharma-to-meet-with-fda-regarding-ampligen-decision-41796.html Hemispherx awaits FDA decision on Ampligen NDA for chronic fatigue syndrome - "The Pink Sheet Daily" https://ca.proactiveinvestors.com/companies/news/91571/hemispherx-awaits-fda-decision-on-ampligen-nda-for-chronic-fatigue-syndrome-the-pink-sheet-daily-37948.html Hemispherx BioPharma (AMEX:HEB) was recently featured in an article in the "The Pink Sheet Daily", which outlines the boost in drug development efforts from the FDA for chronic fatigue syndrome (CFS), and discusses the progress of the company's Ampligen drug - a potential first approved treatment for the disease. 

]]>
Thu, 29 Nov 2012 14:36:00 -0500 https://ca.proactiveinvestors.com/companies/news/91571/hemispherx-awaits-fda-decision-on-ampligen-nda-for-chronic-fatigue-syndrome-the-pink-sheet-daily-37948.html